The FY16
Defense Appropriations Act provides $6 million (M) to the Department of Defense
Tuberous Sclerosis Complex Research Program (TSCRP) to
support innovative, high-impact TSC research. As directed by the
Office of the Assistant Secretary of Defense for Health Affairs, the Defense
Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate
manages the Defense Health Program (DHP) Research, Development, Test, and
Evaluation (RDT&E) appropriation. The managing agent for the
anticipated Program Announcements/Funding Opportunities is the Congressionally
Directed Medical Research Programs (CDMRP).
FY16 TSCRP Program
Announcements and General Application Instructions for the following award
mechanisms are posted on the Grants.gov website.
Focus Areas: The goal of the FY16 TSCRP is to
encourage innovative research aimed at understanding the pathogenesis, and
preventing and treating the manifestations of TSC. Within this context,
the FY16 TSCRP encourages applications that address the critical needs of the
TSC community in one or more of the following FY16 Focus Areas:
·
Understanding
phenotypic heterogeneity in TSC
·
Gaining
a deeper knowledge of TSC signaling pathways and the cellular consequences of
TSC deficiency
·
Improving
TSC disease models
·
Developing
clinical biomarkers for TSC
·
Facilitating
therapeutics and clinical trials research
Exploration – Hypothesis Development Award
Investigators at all academic levels (or equivalent), including
postdoctoral fellows.
Supports the initial
exploration of innovative, high-risk, high-gain, and potentially groundbreaking
concepts in the TSC research field.
Projects involving human
subjects or human biological substances must be exempt under 32 CFR
219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or
21 CFR 56.110.
Preliminary
data is not required.
Research projects must be
innovative, feasible, and supported by a strong rationale.
Clinical trials not allowed.
Maximum funding of $200,000 for
direct costs (plus indirect costs).
Maximum period of performance is 2 years.
Idea Development Award
Established
Investigators:
Independent investigators
with a documented faculty appointment (or equivalent); Or
New Investigators:
Investigators who are early in their faculty appointments or in
the process of developing independent research careers.
Supports ideas that have the potential to yield high-impact
findings and new avenues of investigation.
Preliminary data is expected.
Clinical trials not allowed.
New Investigator Option supports
applicants who early in their faculty appointments or in the process of
developing independent research careers.
Applications from New
Investigators and Established Investigators will be peer- and programmatically
reviewed separately.
Maximum funding of $450,000 for
direct costs (plus indirect costs).
Maximum period of performance is 3 years
Pilot Clinical Trial Award
Must be an independent investigator at or above the level of
Assistant Professor (or equivalent).
Supports exploratory
studies with limited human exposure that produce diagnostic or therapeutic
information, toxicity studies of an intervention, and studies to determine the
mechanism of action and side effects of an intervention.
Aims at collecting
preliminary data to support the rationale and design of subsequent clinical
trial(s).
Preliminary or preclinical data is required
Maximum funding of $300,000 for
direct costs (plus indirect costs).
Maximum period of performance is 2 years.
Postdoctoral Training Award
Must have successfully defended a doctoral thesis or possess an
M.D. degree.
Supports TSC research
training opportunities for postdoctoral trainees who are recent doctoral
graduates.
PIs must have a designated mentor who is an experienced TSC
researcher.
Maximum funding of $150,000 for
direct costs (plus indirect costs).
Maximum period of performance is 3 years.
Synergistic Idea Development Award
Each PI must be an independent investigator at or above the
level of Assistant Professor (or equivalent).
Supports new or existing
partnerships between two or three independent investigators, who
should utilize their complementary and synergistic perspectives to address a
central innovative question or problem in TSC.
PIs are expected to
demonstrate within the application the synergistic components (i.e., leveraging
disciplines, expertise, or critical resources) that will significantly advance
the project such that the research outcomes as a whole will be realized rapidly
and efficiently and could not otherwise be accomplished through independent
efforts of a single PI.
Each
partner will be recognized as a PI, and a separate award will be made to each
PI, even if the PIs are at the same organization.
Preliminary
data is expected.
Clinical trials are not allowed.
Maximum funding of $750,000 for
direct costs (plus indirect costs).
Maximum period of performance is 3 years.
A pre-application (letter of intent) is required and must be
submitted through the electronic Biomedical Research Application Portal (eBRAP)
at https://eBRAP.org prior
to the pre-application deadline. All applications must conform to the
final Program Announcements and General Application Instructions t available
for electronic downloading from the Grants.gov website. The application package
containing the required forms for each award mechanism will also be found on Grants.gov. A listing of
all CDMRP funding opportunities can be obtained on the Grants.gov website by
performing a basic search using CFDA Number 12.420.
Applications must be submitted through the federal government’s
single-entry portal, Grants.gov.
For email notification when Program Announcements are released go to the CDMRP
website (http://cdmrp.army.mil)
and select Subscribe to Funding Opportunities & Program
Communications. For more information about the TSCRP or other
CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
For
questions about the research programs, please contact the MRO Research Grants
& Contracts Team (adm-researchgrants.contracts@monash.edu).
No comments:
Post a Comment